指南与共识慢阻肺哮喘间质性肺疾病

肺部精准医学研究中生物标志物的现状与未来机会:ATS/NHLBI研究声明

Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.
指南 / 共识 · Am J Respir Crit Care Med · 2018-01-01

美国胸科学会与国家心肺血液研究所组织专家评估了肺癌、肺动脉高压、特发性肺纤维化、哮喘、慢阻肺、脓毒症、急性呼吸窘迫综合征、囊性纤维化等肺病生物标志物的现状,发现其进展因病种差异很大,但整体有改善临床照护的潜力;要实现临床转化,需针对未满足的临床需求开展发现、验证、临床效用和成本效果研究,并确保适用于多样化真实人群。

要点

  • 肺病生物标志物检测的临床应用常快于充分数据评估,需系统评价其临床效用。
  • 不同肺病的生物标志物进展差异很大,但整体在改善临床照护方面有巨大潜力。
  • 实现临床转化需针对未满足需求,开展分析验证、临床验证及成本效果研究。

核心结论

  • 肺部精准医学已取得一定进展,但需额外研究评估生物标志物的临床效用、在多样化真实人群中的可推广性及成本效果。

研究设计与样本

  • 美国胸科学会与国家心肺血液研究所组织多学科临床与研究人员,综述肺病生物标志物检测现状并识别知识缺口。

主要发现

  • 生物标志物检测在肺病中的现状因病种不同而高度可变。
  • 生物标志物检测在改善肺病临床照护方面显示出巨大前景。

关键数值与推荐

  • 推动生物标志物广泛临床转化需:解决特定临床未满足需求、支持发现研究、开展分析与临床验证、确保临床效用、促进常规实践采纳。

临床怎么用

  • 临床引入肺病生物标志物检测前,应关注其临床效用证据及在真实人群中的适用性。

局限性

  • 许多生物标志物检测的采纳速度超过足够数据生成与评估,影响临床效用和健康结局改善的判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thousands of biomarker tests are either available or under development for lung diseases. In many cases, adoption of these tests into clinical practice is outpacing the generation and evaluation of sufficient data to determine clinical utility and ability to improve health outcomes. There is a need for a systematically organized report that provides guidance on how to understand and evaluate use of biomarker tests for lung diseases. METHODS: We assembled a diverse group of clinicians and researchers from the American Thoracic Society and leaders from the National Heart, Lung, and Blood Institute with expertise in various aspects of precision medicine to review the current status of biomarker tests in lung diseases. Experts summarized existing biomarker tests that are available for lung cancer, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, asthma, chronic obstructive pulmonary disease, sepsis, acute respiratory distress syndrome, cystic fibrosis, and other rare lung diseases. The group identified knowledge gaps that future research studies can address to efficiently translate biomarker tests into clinical practice, assess their cost-effectiveness, and ensure they apply to diverse, real-life populations. RESULTS: We found that the status of biomarker tests in lung diseases is highly variable depending on the disease. Nevertheless, biomarker tests in lung diseases show great promise in improving clinical care. To efficiently translate biomarkers into tests used widely in clinical practice, researchers need to address specific clinical unmet needs, secure support for biomarker discovery efforts, conduct analytical and clinical validation studies, ensure tests have clinical utility, and facilitate appropriate adoption into routine clinical practice. CONCLUSIONS: Although progress has been made toward implementation of precision medicine for lung diseases in clinical practice in certain settings, additional studies focused on addressing specific unmet clinical needs are required to evaluate the clinical utility of biomarkers; ensure their generalizability to diverse, real-life populations; and determine their cost-effectiveness.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Wu AC, Kiley JP, Noel PJ, et al. Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement. Am J Respir Crit Care Med. 2018. PMID: 30640517. doi:10.1164/rccm.201810-1895ST

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。